What the FDA labels say about taking them together
Paclitaxel and sorafenib
Sorafenib's FDA label of August 28, 2023 names paclitaxel in its contraindications section; the paclitaxel labels PlainMeds reads (4) do not name sorafenib. The sorafenib label: “NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer.”
Check it at the source: the paclitaxel FDA label on DailyMed (effective January 21, 2026, Natco Pharma USA LLC); the sorafenib FDA label on DailyMed (effective August 28, 2023, Bayer HealthCare Pharmaceuticals Inc.).
What does the paclitaxel label say about sorafenib?
Paclitaxel's label (effective January 21, 2026) and its 3 other brand-application labels do not name sorafenib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Paclitaxel), Natco Pharma USA LLC, effective January 21, 2026 (SPL set a1eb16b4-285b-4e81-9c4e-1244d4a52af8), via openFDA; the full label on DailyMed
What does the sorafenib label say about paclitaxel?
Sorafenib label, contraindicationsNEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )].
Sorafenib label, warnings and precautionsObserved with NEXAVAR Administered in Combination with Carboplatin/Paclitaxel and Gemcitabine/Cisplatin in Squamous Cell Lung Cancer In a subset analysis of two randomized controlled trials in chemo-naive patients with Stage IIIB-IV non-small cell lung cancer, patients with squamous cell carcinoma experienced higher mortality with the addition of NEXAVAR compared to those treated with carboplatin/paclitaxel alone (HR 1.81;
Source: FDA drug label (Nexavar), Bayer HealthCare Pharmaceuticals Inc., effective August 28, 2023 (SPL set b50667e4-5ebc-4968-a646-d605058dbef0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Paclitaxel | Sorafenib | |
|---|---|---|
| Labeled for | Breast cancer, Lung cancer | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once